Updated on 16 April 2014
Co-Founder: (From L to R) Ms Florence Leong, Associate Prof Huang Zhiwei and Professor Lawrence Ho
Singapore: Endofotonics, a medical technology company spun off from National University of Singapore (NUS), has developed an in-vivo molecular diagnostic (IMDX) system that enables objective, cancer diagnosis to be available almost instantaneously during endoscopy.
Whilst the current process is highly dependent on the operator's skill and experience in recognising and evaluating tissues structure, clinical diagnosis from IMDX system is non-operator dependent. This is because it is based on molecular information of tissues which is unique and distinct. As the molecular information is analysed by a computer software, diagnosis is provided almost instantaneously during the gastroscopic examinations. This is in contrast to the waiting time of up to a week for current processes, an agonising time lapse that can cause extreme anxiety for patients and their care-givers.
The computer software ensures that diagnosis generated is entirely objective, minimising the dependence on the doctor's skill and experience. It also means that the IMDX system can be operated with minimal training.
The technology for the IMDX system, which was developed in the National University of Singapore, was licensed exclusively to Endofotonics by NUS Industry Liaison Office, part of NUS Enterprise. The NUS Industry Liaison Office has filed several patents on this technology.
"We are extremely excited at the prospect of bringing molecular diagnosis into the body. The objective real time diagnosis made possible will cause a paradigm shift in how diagnosis is made and significantly reduce cancer deaths and burden," said Ms Florence Leong, CEO and Co-founder of Endofotonics.